Seladelpar (Livdelzi, Gilead) is indicated for 'the treatment of primary biliary cholangitis (PBC), including pruritus, in adults in combination with ursodeoxycholic acid (UDCA) who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA'.
The dosage schedule is available in the summary of product characteristics for seladelpar.
The list price of seladelpar is £3,155.00 per 30-tablet pack of 10 mg tablets (excluding VAT; company submission).
The company has a commercial arrangement. This makes seladelpar available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Gilead's webpage on sustainability.